ALK (Anaplastic Lymphoma Kinase, CD246)-specific CARs: New Immunotherapeutic Agents for the Treatment of Pediatric Solid Tumors

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-1-s1-p27
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Targeting High-Risk Pediatric Solid Tumors With CAR T Cells Directed Against ALK (Anaplastic Lymphoma Kinase, CD246)

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

Anaplastic Lymphoma Kinase (ALK)

Science-Business eXchange
2008English

Status of the Anaplastic Lymphoma Kinase (ALK) Gene in Inflammatory Breast Carcinoma

SpringerPlus
Multidisciplinary
2013English

MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Development of Anaplastic Lymphoma Kinase (ALK) Inhibitors and Molecular Diagnosis in ALK Rearrangement-Positive Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2014English

ALK-negative Anaplastic Large Cell Lymphoma

2020English

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2012English

Leukemic Phase of ALK-positive Anaplastic Large Cell Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2013English

Expression of CD8 Is Associated With Non-Common Type Morphology and Outcome in Pediatric Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma

Haematologica
Hematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy